Axcella

87 articles with Axcella

• Axcella to Hold Virtual-Only 2020 Annual Meeting of Stockholders

  5/4/2020

  Axcella (Nasdaq: AXLA), today announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to the continued public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of its employees, stockholders and community.

• Axcella Receives Fourth Patent Covering EMM Compositions

  4/7/2020

  Axcella today announced the issuance of U.S. Patent 10,596,136. This patent broadly covers the use of the company’s initial muscle product candidate, AXA

• Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research

  3/5/2020

  Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it will give an oral presentation at the 2020 International Conference on Frailty and Sarcopenia (ICFSR) in Toulouse, France on March 12, 2020.

• Axcella Completes Enrollment of Subjects in AXA1665-002 Study

  2/26/2020

  Feb. 26, 2020 12:30 UTC 60 subjects enrolled in AXA1665-002 Top-line data expected in mid-2020 IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of 2020 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex d

• Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference

  2/19/2020

  Feb. 19, 2020 13:00 UTC Presentation and webcast to take place at 9:00 a.m. ET on February 26 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26,

• Axcella to Present at J.P. Morgan Healthcare Conference

  1/9/2020

  Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, announced that President and CEO Bill Hinshaw will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 16, 2020 at 8:30 a.m. PT.

• Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones

  1/8/2020

  Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks

• Axcella Presents Data at ASH Annual Meeting

  12/7/2019

  Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health

• Axcella Announces Issuance of Broad Patent Covering EMM Compositions

  11/20/2019

  Covers NASH candidates AXA1125 and AXA1957 as well as other Endogenous Metabolic Modulator (EMM) compositions

• Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010

  11/6/2019

  Non-IND clinical study initiated to assess safety, tolerability and blood physiology; first subjects with sickle cell disease enrolled

• Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update

  8/12/2019

  Axcella Health Inc. announced financial results for the second quarter ended June 30, 2019 and provided a company update.

• 

  BioSpace's List of May 2019 Life Science IPOs

  5/23/2019

  A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
• 

  4 Biotech Companies List on the Nasdaq Today

  5/9/2019

  Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.

• Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use

  4/2/2019

  Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio

• 

  BioSpace Movers and Shakers: March 29

  3/29/2019

  Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.

• Axcella to Present Late-Breaker Data on Lead AXA™ Candidate, AXA1665 at EASL, the International Liver Congress™

  3/27/2019

  Axcella Health announced a late-breaker poster presentation for their novel endogenous metabolic modulator composition, AXA1665 in subjects with mild and moderate hepatic insufficiency.

• Axcella Presents Mechanistic Data Demonstrating that AXA1125 Modulated Liver Metabolic, Inflammatory and Fibrotic Pathways

  1/24/2019

  Data further support compositions of Endogenous Metabolic Modulators (EMM) as novel multifactorial assets with the potential to support health or become therapeutically relevant

• Axcella to Present Update at the 37th Annual JP Morgan Healthcare Conference

  1/3/2019

  Axcella Health Inc. (the “Company,” “Axcella,” or “we”), a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Bill Hinshaw, President and CEO, will present a corporate update at the 37th Annual JP Morgan Healthcare Conference, taking place January 7-10, 2019, at the Westin St. Francis Hotel in San Francisco, CA.

• 

  BioSpace Movers and Shakers Oct. 29

  10/29/2018

  Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.

• Axcella to Present New Data at the Annual 2018 AASLD Liver Meeting

  10/22/2018

  Effective therapies for NAFLD require coordinated reprogramming of cellular physiology as multiple pathways drive liver injury and disease progression.